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ABSTRACT
Background: The Democratic Republic of the Congo (DRC) belongs to the 22 tuberculosis 
(TB) high-burden countries and to the 27 high-burden multidrug-resistant (MDR)-
TB countries. To date, there are no data on the genetic diversity of Mycobacterium 
tuberculosis in the DRC. 
Objective: To describe the genetic diversity and the distribution of drug resistance 
conferring mutations of clinical M. tuberculosis isolates from the DRC.
Design: We analysed consecutive M. tuberculosis single patient isolates cultured in 
2010 at the laboratory of the National TB Control Programme in Kinshasa. 
Setting: National TB Control Programme in Kinshasa, DRC.
Results: Isolates from 50 patients with pulmonary TB were analysed, including 45 
patients (90%) who failed treatment. All isolates belonged to the Euro-American 
lineage (main phylogenetic Lineage 4). Six different spoligotype families were 
observed within this lineage, including LAM (20 patients, 40%), T (15 patients; 30%), 
U (4 patients; 8%), S (3 patients; 6%), Haarlem (2 patients; 4%), and X (1 patient; 2%). 
No M. africanum strains were observed. The most frequently detected drug resistance-
conferring mutations were rpoB S531L and katG S315T1. Various other mutations, 
including previously unreported mutations, were detected.
Conclusions: The Euro-American lineage dominates in the DRC, with substantial 
variation in spoligotype families. This study fills an important gap on the molecular 
map of M. tuberculosis in sub-Saharan Africa.
INTRODUCTION 
The Democratic Republic of the Congo (DRC) has 
an estimated population of 63 million and a gross 
national income per capita of 280 US$. The DRC is 
one of 22 tuberculosis (TB) high-burden countries 
with an estimated incidence of 392 new TB cases 
per 100,000 per year (1). The country also belongs to 
the 27 countries with a high burden of multidrug-
resistant (MDR) TB, the prevalence of MDR among 
new cases is 2.3% (2). 
 Mycobacterium tuberculosis complex (MTBC) 
has a global phylogeographic population structure 
consisting of six main phylogenetic lineages (3): 
Lineage 1 (known as Indo-Oceanic lineage), Lineage 
2 (known as East-Asian lineage), Lineage 3 (known 
as Delhi/CAS), Lineage 4 (known as Euro-American 
lineage), and Lineages 5/6 (known as West African 
lineages 1 and 2 also known as M. africanum). 
These bacterial lineages are associated with specific 
geographic regions and human populations (3-5). 
Lineage 4 represents the M. tuberculosis family 
with the largest geographical spread and includes 
spoligotype strain families such as “Haarlem 
(H)” or “Latin-American-Mediterranean (LAM)”. 
There is increasing evidence that strain diversity in 
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M. tuberculosis plays a role in the presentation of 
disease in humans (3,6) and in animal models (7). 
For example, a study from West Africa found a 
lineage-dependent rate of progression from infection 
to active disease comparing M. africanum versus M. 
tuberculosis (8). A study from Vietnam showed that 
a higher proportion of adults with pulmonary TB 
caused by Lineage 4 (Euro-American lineage) had 
a consolidation on the chest X-ray radiographs, and 
that TB meningitis caused by Lineage 2 (East-Asian 
lineage) was associated with disease progression and 
leukocyte count in cerebrospinal fluid (9). Another 
study from Vietnam found that Lineage 4 strains were 
less likely to cause TB meningitis compared to other 
lineages (10). Furthermore, M. tuberculosis strains 
belonging to Lineage 2 (which includes the Beijing 
genotype) are associated with drug resistance and 
infection with the human immunodeficiency virus 
(HIV) (7, 11, 12), and have been rapidly emerging in 
some areas, for example in Cape Town, South Africa 
(11, 13), or in the Canary Islands in Spain (14). Finally, 
recent studies have reported associations between 
M. tuberculosis lineages and specific human genetic 
polymorphisms in genes associated with the immune 
system (10, 15). Taken together, M. tuberculosis is 
more genetically diverse than previously thought 
(16) and this genetic diversity may translate into 
phenotypic effects.
 To date, there are no data on the genetic diversity 
of M. tuberculosis or on the distribution of drug 
resistance conferring mutations in the DRC. Therefore, 
we characterised clinical M. tuberculosis isolates to 
gain insights into the genetic population structure of 
M. tuberculosis and the frequency of drug resistance 
conferring mutations in the DRC.
MATERIALS AND METHODS
Study setting: We analysed consecutive M. tuberculosis 
single patient isolates cultured in 2010 at the 
laboratory of the National TB Control Programme 
in Kinshasa. Cultures were mainly done in patients 
failing treatment and when (multi) drug resistance 
was suspected. The National TB Control Programme 
in DRC runs TB testing and treatment centres 
throughout Kinshasa and other parts of the country. 
Its TB laboratory in Kinshasa acts as the reference 
laboratory for the country following international 
guidelines (17). Clinical data were obtained from the 
National TB Control Programme.
Strain culturing and DNA extraction:  Clinical specimens 
were processed and strains cultured on Löwenstein-
Jensen medium according to international guidelines 
(17) at the TB reference laboratory in Kinshasa. 
Standard phenotypic drug susceptibility testing 
(DST) for isoniazid and rifampicin were performed 
by proportion method according to international 
guidelines (17). 
Molecular investigations: DNA was extracted from 
subcultures according to standard laboratory 
procedures. Mutations in katG, inhA, and rpoB, 
which are known to confer resistance to isoniazid 
and rifampicin, respectively, were determined 
using the GenoType MTBDRplus line probe assay 
(Hain Lifescience, Germany; katG, inhA, rpoB genes); 
and complemented by PCR amplification and 
direct sequencing of PCR products as described 
previously (18,19). Determination of the main 
M. tuberculosis lineages was performed by single 
nucleotide polymorphisms (SNPs) using multiplex 
real-time PCR with fluorescence-labelled probes 
(Taqman, Applied Biosystems, USA) as described 
before (20). The SNP used to define Lineage 4 
was originally described by Sreevatsan et al. (21) 
and shown to be specific to this lineage (20). 
M. tuberculosis isolates were further genotyped by 
spoligotyping as previously described (22). Spoligo-
International-Type (SIT) numbers were assigned 
using data published in the fourth international 
spoligotyping database (SpolDB4) (22). Spoligotype 
families were used to define sub-lineages within the 
main M. tuberculosis lineages (23). 
Ethical approval: The study was approved by the 
Ethics Committee of the Kinshasa School of Public 
Health in Kinshasa, DRC. No informed consent was 
required by the Ethics Committee.  All data and strains 
were collected in the context of routine care and no 
additional data collection or contact with patients 
occurred for this study. The data were completely 
de-identified before analysis using unique study 
numbers.
RESULTS
Patient characteristics: A total of 50 pulmonary TB 
patients were included. Median age was 28 years 
(interquartile range 26-34 years), 33 (66%) were male, 
four (8%) were known to be HIV-infected (Table 1). 
Treatment failure was the most frequent TB category 
(45 patients; 90%), and the patients were primarily 
from the capital Kinshasa (33 patients; 66%) and from 
Lubumbashi (9 patients; 18%). Figure 1 shows the 
geographical origin of the 50 isolates.
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Figure 1
Origin of the clinical Mycobacterium tuberculosis isolates in the Democratic Republic of the Congo (shaded in grey)
Table 1
Clinical characteristics of the 50 tuberculosis (TB) patients from the Democratic Republic of Congo 
included in the study
Characteristic Value
Age, median (interquartile range), years 28(26-34)
Sex, n (%) 
 Male 33(66)
 Female 17(34)
HIV status, n (%) 
 HIV-positive 4(8)
 Not determined 46(92)
TB categories, n (%) 
 Treatment failure 45(90)
 New case 3(6)
Previous TB 1(2)
 Recurrent case 1(2)
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Genetic diversity of M. tuberculosis: The molecular 
analyses showed that all isolates belonged to 
Lineage 4 (Euro-American lineage). Considerable 
genetic diversity was, however, observed within 
this lineage based on spoligotyping. The most 
frequent spoligotype family was the LAM (Latin-
American-Mediterranean) family (20 isolates; 40%) 
and the T-family (the “ill-defined” family; 15 isolates; 
30%), followed by the S, U, H and X families (Table 
2). One strain belonged to the Cameroon family 
(“LAM10_CAM”), and two strains to the Zimbabwe 
family (“LAM11_ZWE”) (Table 3). Table 3 details the 
spoligotyping results according to the classification of 
SpolDB4, using the SITVIT molecular database, which 
is available at http://www.pasteur-guadeloupe.
fr:8081/SITVITDemo/index.jsp. Spoligotypes are 
patterns formed by the presence or absence of 43 
spacers in the DR locus of Mycobacterium tuberculosis 
and these patterns (Table 3). 
Table 2
Molecular data of the 50 clinical Mycobacterium tuberculosis isolates
Characteristic         n(%)
 All   MDR 
 n=50  n=28
Spoligotyping families, n (%)   
 LAM (Latin-American-Mediterranean)  20(40.0) 14(50.0)
 T (ill-defined “lineage”) 15(30.0) 5(17.8)
 U  4(8.0) 3(10.7)
 S  3(6.0) 3(10.7)
 H  2(4.0) 1(3.6) 
 X  1(2.0) 1(3.6)
 Undesignated  5(10.0) 1(3.6
Main M. tuberculosis lineages, n (%)   
 Lineage 4 (Euro-American lineage) 50(100) 28(100) 
 Other lineages 0 0 
Drug resistance mutations, n (%)   
 rpoB (codon)    
 S531L 21(42.0) 17(60.7) 
 D516V 6(12.0) 4(14.3) 
 S522Q 3(6.0) 2(7.1) 
 N518S1/L533P 1(2.0) 1(3.6) 
 H526H12 1(2.0) 1(3.6) 
 H526N 1(2.0) 0
 H526D 1(2.0) 0
 S531W 1(2.0) 1(3.6)
 P535S 1(2.0) 0
 Deletion Q-F-M (513-515)1 1(2.0) 0
katG (codon)   
 S315T1 (AGC>ACC) 31(62.0) 24(85.7) 
 L333R1 2(4.0) 2(7.1) 
 S315N 2(4.0) 0
 M377R1 1(2.0) 1(3.6) 
inhA Promote  
 C15T 4(8.0) 2(71)
 T8C 1(2.0) 1(3.6)
MDR, multidrug-resistant as determined by phenotypic drug susceptibility testing
1first described in this study
2synonymous mutation
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Table 3
Spoligotyping results from the 50 clinical Mycobacterium tuberculosis isolates according to the definition in 
SpolDB4 database using SITVIT2 (http://www.pasteur-guadeloupe.fr:8081/SITVITDemo/index.jsp)
Drug resistance: Phenotypic DST results showed that 28 
isolates were MDR strains. Analysis of drug resistance 
mutations revealed rpoB S531L and katG S315T1 
(AGC>ACC) as the most frequent mutations (Table 
2). But other mutations were also detected, including 
rpoB mutations N518S, the rpoB deletion 513-515, katG 
mutation L333R and katG mutation M377R. We also 
detected new mutations that had never been reported 
before according to the TB Drug Resistance Mutation 
database such as rpoB mutations N518S, the rpoB 
deletion 513-515, katG mutation L333R and katG mutation 
M377R. Comparing phenotypically confirmed MDR 
with non-MDR isolates (with a DST result), the LAM 
spoligotyping family was more frequent (50.0% versus 
16.7%), and T-family less frequent (17.8% versus 50.0%) 
in MDR isolates (Fisher’s exact test p=0.03).
DISCUSSION
This is the first report on the genetic diversity of M. 
tuberculosis in the DRC, one of the largest and most 
populous countries in sub-Saharan Africa, and a country 
that is heavily affected by the global epidemic of TB. 
We found that all M. tuberculosis strains belonged to the 
Euro-American lineage (Lineage 4) but that there was 
considerable genetic diversity of spoligotyping families 
such as LAM, T, X, H and S. We also found that rpoB 
S531L and katG S315T1 were the most frequent drug 
resistance-conferring mutations, which is consistent with 
reports from most other geographic regions. 
 The Euro-American lineage represents the M. 
tuberculosis family with the largest geographical spread 
and includes spoligotype families such as “Haarlem” 
or “LAM” (3). The high proportion of the LAM (Latin-
American-Mediterranean) family in our sample is 
consistent with findings from other countries in Southern 
Africa, including South Africa (F11 genotype) (24) and 
Zimbabwe (“Zimbabwe-family”) (25), and is possibly 
linked to the contact with Europeans during colonial 
times (16). Interestingly, the Cameroon family which 
Spoligotype description SIT Clade Spoligo n(%) 
    family  
 42 LAM9 LAM 6(12.0)
 20 LAM1 LAM 5(10.0)
 52 T2 T 5(10.0)
 144 T1 T 5(10.0)
 34 S S 3(6.0)
 17 LAM2 LAM 2(4.0)
 106 U(LAM3) U 2(4.0)
 737 LAM9 LAM 2(4.0)
 1548 U U 2(4.0)
 Orphan Undesignated Undesignated 2(4.0)
 Orphan Undesignated Undesignated 2(4.0)
 50 H3 H 1(2.0)
 53 T1 T 1(2.0)
 59 LAM11_ZWE LAM 1(2.0)
 61 LAM10_CAM LAM 1(2.0)
 73 T2-T3 T 1(2.0)
 95 LAM6 LAM 1(2.0)
 137 X2 X 1(2.0)
 175 T2 T 1(2.0)
 241 T1 T 1(2.0)
 1155 H1 H 1(2.0)
 1284 T1 T 1(2.0)
 1545 LAM9 LAM 1(2.0)
 1549 LAM11_ZWE LAM 1(2.0)
 Orphan Undesignated Undesignated 1(2.0) 
SIT, Spoligotype international type
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is the major group of M. tuberculosis strains in the 
neighbouring countries of Chad (26) and Cameroon 
(27,28) does not seem to occur very frequently in the 
DRC. M. africanum lineages have not been detected in  the 
DRC, Angola (29) or Chad (26). However, M. africanum 
was found to be declining in Cameroon in the last three 
decades, and the same may be true for DRC. 
 Despite major improvements in treatment and 
control, TB remains a major public health problem 
worldwide, particularly in the context of MDR and 
extensively drug-resistant (XDR) TB (2,30). Drug 
susceptibility can be tested by culture methods based on 
bacterial growth, or alternatively by molecular methods 
detecting drug resistance-associated gene mutations (31). 
Antibiotic resistance mutations are usually associated 
with a fitness cost and recent studies suggest that the 
genetic background in M. tuberculosis strains can influence 
the relative fitness (32-34). Interestingly, M. tuberculosis 
strains with low- or no-cost resistance mutations (e.g. 
rpoB S531L) are also the most frequent among clinical 
isolates (33). In our study, we found that rpoB S531L and 
katG S315T1 were the most frequent drug resistance-
conferring mutations in the DRC. We also detected new 
mutations that have never been reported before, such as 
rpoB mutations N518S, the rpoB deletion 513-515, katG 
mutation L333R and katG mutation M377R. rpoB L533P 
associated with low-level rifampicin resistance (35) was 
present in one strain together with rpoB mutation N518S. 
Such low-level drug resistance mutations are difficult 
to detect using liquid culture based drug resistance 
testing (35,36). The frequency of these low-level drug 
resistance mutations in the DRC and the significance 
of the mutations discovered in this study will need to 
be evaluated in larger studies.
 Our study has several limitations. We could not 
exclude with certainty that other lineages and less 
common spoligotyping families or resistance mutations 
existed due to the relatively small sample size. Secondly, 
we stress that the strains analysed among selected TB 
patients failing treatment mainly in Kinshasa did not 
reflect the M. tuberculosis strains causing the disease in 
the country at large, but will be representative of those 
sent to the reference laboratory and cultured.
In conclusion, the Euro-American lineage dominates 
in the DRC, with substantial variation in spoligotype 
families. To our knowledge, this is the first study on the 
genetic diversity of M. tuberculosis in the DRC, mainly in 
Kinshasa, one of the largest cities in sub-Saharan Africa 
which is of great interest due to the high TB and MDR 
TB burden (1,2). In-depth knowledge of the population 
biology and epidemiology of M. tuberculosis is essential 
for the development of new TB diagnostics, drugs, 
and vaccines (3,37,38). Future studies on the molecular 
epidemiology of TB in DRC, with a special focus on 
MDR and HIV-infected populations, will provide a more 
complete picture of the distribution of M. tuberculosis 
genetic diversity in this part of the world.
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